What We Do
ExOcular is revolutionizing the management of
severe eye diseases by measuring biomarkers isolated from exosomes.
We're developing a robust portfolio of blood-based multiplex tests. Clinical studies revealed eye-specific biomarkers that change as the disease progresses.
Our tests provide precise, early, and actionable insights, paving the way for personalized and transformative patient care.
Our analysis algorithms generate a quantitative Disease Severity Score. Results empower physicians with unparalleled insights to deliver earlier referrals and more individualized treatments.
Exosomes Make the Difference
Exosomes carry proteins, DNA and RNA that originate from specific organs and tissues. Because the cargo is disease-specific and changes with the condition, biomarkers isolated from exosomes are well-suited for diagnostic, prognostic and monitoring indications.
Their lipid bilayer protects biomarkers from degradation. Biomarkers isolated from exosomes can be much more concentrated than direct blood-based biomarkers, so quantification is more reproducible.
The Impact of Severe Eye Disease
The incidence and prevalence of severe eye diseases increase as people age. Our initial focus is on patients with diabetic retinopathy and age-related macular degeneration)— the leading causes of blindness.
​
Diabetic Retinopathy (DR) is the leading cause of blindness for working-age people and the third leading cause of blindness. 38.4M Americans have
diabetes; and 9.6M people have DR (26% of diabetics). 70% of patients do not know they have it.
-
Action: Early detection enables treatment with simpler surgical procedures and/or medications that can save vision in both eyes.
Age-Related Macular Degeneration (AMD) is a progressive retinal disease and is a leading cause of blindness in people over 60.
-
Action: High-risk patients can be treated earlier to delay blindness. Our panels can be used to qualify patients for specialty drugs & to measure efficacy.
Unmet Clinical Need
Healthcare providers need an easy and accurate way to risk-stratify patients with severe vision-threatening diseases and to monitor treatment effectiveness.
Our Solution
